About Turn Therapeutics Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://turntherapeutics.com
Frequently Asked Questions
What is the 52-week range for TTRX?
The 52-week high is $26.5 and the 52-week low is $2.5701.
What is the P/E ratio for TTRX?
The P/E ratio data is currently unavailable.
What is the dividend yield for TTRX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -281.64%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 24.75.
Analyst Recommendation Trends
Wall Street analyst consensus for TTRX over the last few months:
Latest TTRX News
This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70; EFSC Buy, $70.
LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.
WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target
WBB Securities analyst Karen Sterling downgrades Turn Therapeutics (NASDAQ:TTRX) from Hold to Sell and announces $10 price target.
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
WESTLAKE VILLAGE, Calif., September 10, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum as follows:
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
WESTLAKE VILLAGE, Calif., September 09, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today announced the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology (NASDAQ:PDSB)
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
Martin Dewhurst appointed as independent director and member of the Audit and Compensation CommitteesVeteran healthcare executive brings more than 30 years of leadership, governance, and strategic advisory experience ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-04 | Dewhurst Martin William | +71,666 | - | - |
| 2026-06-04 | Kester Kent Edward | +83,334 | - | - |
| 2026-06-04 | Gengos Andrew | +95,000 | - | - |
| 2026-06-04 | GOLDEN ARTHUR F | +89,584 | - | - |
| 2026-05-28 | BEB Holdings, LLC | +300,000 | - | - |
| 2026-05-28 | BEB Holdings, LLC | -300,000 | - | - |
| 2026-05-28 | BEB Holdings, LLC | +300,000 | - | - |
| 2026-05-28 | BEB Holdings, LLC | -300,000 | - | - |
| 2026-04-02 | BEB Holdings, LLC | -300,000 | - | - |
| 2026-04-02 | GOLDEN ARTHUR F | +300,000 | - | - |
| 2026-04-01 | BEB Holdings, LLC | +160,000 | - | - |
| 2026-04-01 | Chaudhary Zuraiz | +80,000 | - | - |
| 2026-01-07 | Dewhurst Martin William | +21,882 | - | - |
| 2025-12-12 | Chaudhary Zuraiz | +2,500 | $3.5 | $8,750 |
| 2025-11-24 | GOLDEN ARTHUR F | +9,868 | $3.44 | $33,946 |
| 2025-11-21 | GOLDEN ARTHUR F | +20,532 | $2.87 | $58,927 |
| 2025-11-21 | Chaudhary Zuraiz | +1,000 | $3.29 | $3,290 |
| 2025-11-20 | Chaudhary Zuraiz | +1,450 | $2.61 | $3,785 |
| 2025-11-17 | Chaudhary Zuraiz | +2,500 | $3.62 | $9,050 |
| 2025-10-23 | Chesed Abraham | +14,286 | $4.6 | $65,716 |
| 2025-10-23 | Chaudhary Zuraiz | +5,050 | $4.95 | $24,998 |
| 2025-10-23 | GOLDEN ARTHUR F | +20,202 | $4.95 | $100,000 |
| 2025-10-08 | Ghodadra Neilesh Shailesh | +10,000 | - | - |
| 2025-10-08 | Kester Kent Edward | +10,000 | - | - |
| 2025-10-08 | Chaudhary Zuraiz | +240,000 | - | - |
| 2025-10-08 | Gengos Andrew | +10,000 | - | - |
| 2025-10-08 | GOLDEN ARTHUR F | +10,000 | - | - |